Comparative Rates of Adverse Events with 2-Hour versus 4-Hour Infusion of Total Dose Intravenous Iron Polymaltose

Arumugam Manoharan, William Alexander, Rajeev Ramakrishna, Janet Legge, John Uebel

Illawarra Private Cancer Care Centre, Wollongong, Australia.
Southern Sydney Haematology, Kogarah, Australia; Illawarra Private Cancer Care Centre, Wollongong, Australia; Graduate School of Medicine, University of Wollongong, New South Wales, Australia.

DOI: 10.4236/ijcm.2014.54025                

Abstract

Background and aim of the study: Patients with iron deficiency (ID) who are unable to tolerate or show sub-optimal response to oral iron therapy are candidates for parenteral iron therapy. This study evaluated the patient safety and tolerance of iron polymaltose given either as a 2-hour infusion or as a 4-hour infusion. Methods: A total of 243 patients with ID were randomized alternatively to receive iron polymaltose infusion either as a 2-hour infusion or as a 4-hour infusion. All patients received pre-medication with certizine hydrochloride 10 mg PO one-hour before infusion and hydrocortisone 50 mg IVI immediately before infusion. Infusion related adverse events/side-effects during the infusion and over the next seven days were documented and graded as mild, moderate or severe. Results: The age of the patients ranged from 17 years to 92 years (mean 55.5 yr); M:F = 1:3.5. One hundred and twenty-two patients were in the 2-hour arm (M:F = 1:5; mean age 52.9 yr) and 121 were in the 4-hour arm (M:F = 1:2.6; mean age 58.1 yr). Iron infusion therapy was generally well tolerated by patients in both arms. Adverse events/side effects were documented in 14 patients in each arm (22 events in the 2-hour arm and 20 in the 4-hour arm) and included aches and pains, cannula-site pain/swelling, nausea, abdominal cramps, rash, vagal response, metallic taste, hot flushes and headaches. In most patients, these events were mild and none had any severe events. Conclusion: The incidence of adverse events with 2-hour infusion of iron polymaltose is similar to that observed with 4-hour infusion of iron polymaltose.

Keywords

Iron Deficiency; Rapid Iron Polymaltose Infusion

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	E. Beutler, “Disorders of Iron Metabolism in Williams Hematology,” In: M. A. Lichtman, E. Beutler, T. J. Kipps, U. Seligsohn, K. Kaushansky and J. F. Prchol, Eds., Williams Hematology, Mc-Graw-Hill, New York, 2006, p. 518.
[2]	M. B. Zimmermann and R. F. Hurrell, “Nutritional Iron Deficiency,” Lancet, Vol. 370, No. 9586, 2007, pp. 511-520.
[3]	A. Daniilidis, A. Giannoulis and C. Pantelis, et al., “Total Infusion of Low Molecular Weight Iron-Dextran for Treating Post-Partum Anemia,” Clinical and Experimental Obstetrics and Gynecology, Vol. 38, No. 2, 2011, pp. 159-161.
[4]	F. Beigel, B. Lohn, R. P. Laubender, et al., “Iron Status and Analysis of Efficacy and Safety of Ferric Carboxymaltose Treatment in Patients with Inflammatory Bowel Disease,” Digestion, Vol. 85, 2012, pp. 47-54. http://dx.doi.org/10.1159/000333091
[5]	M. L. Haines and P. R. Gibson, “Delayed Reactions to Total Dose Intravenous Iron Polymaltose,” Internal Medicine Journal, Vol. 39, No. 4, 2009, pp. 252-255. http://dx.doi.org/10.1111/j.1445-5994.2009.01898.x
[6]	A. Manoharan, R. Ramakrishna and B. Pereira, “Delayed Adverse Reactions to Total-Dose Intravenous Iron Polymaltose,” Internal Medicine Journal, Vol. 39, No. 12, 2009, p. 857. http://dx.doi.org/10.1111/j.1445-5994.2009.02077.x
[7]	M. Garg, G. Morrison, A. Friedman, A. Lau, D. Lau and P. R. Gibson, “A Rapid Infusion Protocol Is Safe for Total Dose Iron Polymaltose: Time for Change,” Internal Medicine Journal, Vol. 41, No. 7, 2011 pp. 548-554. http://dx.doi.org/10.1111/j.1445-5994.2010.02356.x
[8]	E. Newnham, I. Ahmad, A. Thornton and P. R. Gibson, “Safety of Iron Polymaltose Given as a Total Dose Iron Infusion,” Internal Medicine Journal, Vol. 36, No. 10, 2006, pp. 672-674. http://dx.doi.org/10.1111/j.1445-5994.2006.01156.x
[9]	Department of Health, “Guiding Principles for the Development of Intravenous (IV) Iron Infusion Practice,” Department of Health, Victoria, 2013.
[10]	“Product Information: Ferinject (Ferric Carboxymaltose) Vifor Pharma/Aspen Australia,” 2012.
[11]	M. Naim and J. Hunter, “Intravenous Iron Replacement Management in General Practice,” Australian Family Physician, Vol. 39, No. 11, 2010, pp. 839-841.
[12]	A. K. Alhossain and A. E. Dennis, “Iron Deficiency Anaemia in Pregnancy and Postpartum: Pathophysiology and Use of Oral versus Intravenous Iron Therapy,” Journal of Pregnancy, 2012, Article ID: 630519.